Getting under Our Skin: The Evolving Field of Transdermal Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Getting under Our Skin: The Evolving Field of Transdermal Delivery
A book reviews new agents and delivery methods for various dermal applications to foster innovation and promote knowledge.


Pharmaceutical Technology


Harvinder Singh Gill
Until recently, only small and lipophilic molecules could penetrate the skin. But, recent advances in transdermal drug delivery have opened the skin barrier to hydrophilic molecules and macromolecules, including peptides and proteins. Pharmaceutical applications like vaccination and insulin delivery are already in the pipeline of many transdermal drug-delivery companies.

The book Skin Delivery Systems: Transdermals, Dermatologicals, and Cosmetic Actives brings together recent advances in the cosmetic, dermatological, and transdermal fields into a single volume to enable cross-disciplinary learning and innovation.

About half of the book, namely the first three sections, is devoted to a discussion of the cosmetic and dermatological fields, including the recent active agents. The topics examined in the first three sections include the cellular and molecular basis for skin reactivity, dry-skin and antiwrinkle treatment, and corneotherapy—a treatment modality of the stratum corneum to relieve dermal disorders.




The remaining half of the book, the last two sections, provides a brief review of the newest drug-delivery technologies for topical skin and systemic delivery. These sections are of most relevance to Pharmaceutical Technology readers interested in transdermal drug delivery. In them, the authors describe some of the latest drug-delivery methods such as emulsions, polymer-based skin-delivery systems, and nanoparticles for delivery of molecules to the skin. Iontophoresis and ultrasound are mentioned only briefly.

The book concludes with a discussion of chemical enhancers and some of the recent transdermal drug-delivery technologies such as pulsatile drug delivery and microneedles. The authors also describe the potential of new high-throughput screens to search quickly for better chemical enhancers.


Skin Delivery Systems: Transdermals, Dermatologicals, and Cosmetic Actives, John J. Wille, Ed., Blackwell Publishing, Ames, IA, 2006, 404 pp., ISBN 9780813808482.
Skin Delivery Systems is written for scientists experienced in the dermatological or transdermal fields. Since only recent advances in transdermal drug delivery have been described, readers may like to refer to basic transdermal drug-delivery texts such as Transdermal Drug Delivery, edited by R.H. Guy and J. Hadgraft (New York, Marcel Dekker, 2003, 383 pp., ISBN 082470861X) for fundamental knowledge in the field. Furthermore, many transdermal delivery systems such as sonophoresis, iontophoresis, and other physical approaches only receive a brief mention, and the book lacks detailed discussion of these subjects.

Overall, the book covers a broad variety of topics. It would further benefit from a chapter that synthesized the breadth of information into a vision for the field. This synthesis would help readers better appreciate the interdisciplinary connections between the cosmetic, dermatological, and transdermal delivery fields, and encourage cross-disciplinary innovation.

Harvinder Singh Gill is a research associate at the Georgia Institute of Technology, 315 Ferst Dr., Atlanta, GA 30332, tel. 404.385.1314,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here